DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $97,937,297 | -7.2% | 394,749 | -10.2% | 0.20% | -9.8% |
Q2 2023 | $105,536,640 | -40.3% | 439,736 | -37.5% | 0.22% | -42.3% |
Q1 2023 | $176,875,868 | +2.4% | 703,116 | +7.8% | 0.39% | -1.5% |
Q4 2022 | $172,728,010 | +27.6% | 652,370 | +24.5% | 0.39% | +19.4% |
Q3 2022 | $135,378,000 | -8.3% | 524,133 | -11.2% | 0.33% | -1.2% |
Q2 2022 | $147,640,000 | -44.5% | 590,322 | -34.9% | 0.33% | -33.9% |
Q1 2022 | $266,043,000 | -13.5% | 906,974 | -3.0% | 0.50% | -9.5% |
Q4 2021 | $307,697,000 | +13.6% | 935,221 | +5.1% | 0.56% | +11.2% |
Q3 2021 | $270,946,000 | +20.0% | 889,980 | +5.7% | 0.50% | +28.4% |
Q2 2021 | $225,838,000 | +15.3% | 841,704 | -3.3% | 0.39% | +22.2% |
Q1 2021 | $195,860,000 | +5.8% | 870,183 | +4.1% | 0.32% | -2.4% |
Q4 2020 | $185,053,000 | +6.1% | 835,754 | +1.7% | 0.33% | +11.2% |
Q3 2020 | $174,357,000 | +6.1% | 822,167 | -13.8% | 0.30% | +10.9% |
Q2 2020 | $164,397,000 | -6.6% | 953,743 | -25.1% | 0.27% | -10.1% |
Q1 2020 | $176,093,000 | -41.0% | 1,273,816 | -34.7% | 0.30% | -12.7% |
Q4 2019 | $298,306,000 | -19.9% | 1,950,603 | -24.5% | 0.34% | -22.6% |
Q3 2019 | $372,302,000 | -4.3% | 2,583,278 | -6.1% | 0.44% | +0.9% |
Q2 2019 | $389,070,000 | +14.1% | 2,751,355 | +5.3% | 0.43% | +19.9% |
Q1 2019 | $340,981,000 | +30.0% | 2,612,082 | +2.7% | 0.36% | +19.1% |
Q4 2018 | $262,228,000 | -10.0% | 2,542,944 | -5.2% | 0.30% | +9.0% |
Q3 2018 | $291,498,000 | +62.8% | 2,682,662 | +48.2% | 0.28% | +55.0% |
Q2 2018 | $179,103,000 | +102.3% | 1,810,036 | +100.2% | 0.18% | +89.5% |
Q1 2018 | $88,530,000 | -19.3% | 904,197 | -23.5% | 0.10% | -17.4% |
Q4 2017 | $109,719,000 | +39.4% | 1,182,065 | +28.9% | 0.12% | +22.3% |
Q3 2017 | $78,690,000 | +7.6% | 917,353 | +5.8% | 0.09% | -3.1% |
Q2 2017 | $73,156,000 | -7.1% | 866,883 | -5.9% | 0.10% | -7.6% |
Q1 2017 | $78,773,000 | +7.4% | 921,001 | -2.2% | 0.10% | +4.0% |
Q4 2016 | $73,340,000 | +0.0% | 942,182 | +0.7% | 0.10% | -9.8% |
Q3 2016 | $73,325,000 | +19.9% | 935,390 | +54.5% | 0.11% | +3.7% |
Q2 2016 | $61,168,000 | +11.6% | 605,623 | +4.8% | 0.11% | +9.1% |
Q1 2016 | $54,825,000 | +25.0% | 577,956 | +22.4% | 0.10% | +28.6% |
Q4 2015 | $43,843,000 | +27.7% | 472,044 | +17.2% | 0.08% | +11.6% |
Q3 2015 | $34,321,000 | +21.2% | 402,783 | +21.8% | 0.07% | +23.2% |
Q2 2015 | $28,309,000 | -57.7% | 330,751 | -58.1% | 0.06% | -63.4% |
Q1 2015 | $66,989,000 | -6.6% | 789,034 | -5.7% | 0.15% | +2.0% |
Q4 2014 | $71,694,000 | +100.8% | 836,473 | +78.0% | 0.15% | +53.1% |
Q3 2014 | $35,696,000 | -10.1% | 469,811 | -6.9% | 0.10% | -8.4% |
Q2 2014 | $39,728,000 | +161.7% | 504,617 | +149.3% | 0.11% | +132.6% |
Q1 2014 | $15,181,000 | +112.3% | 202,417 | +118.6% | 0.05% | +119.0% |
Q4 2013 | $7,150,000 | +116.6% | 92,617 | +94.5% | 0.02% | +75.0% |
Q3 2013 | $3,301,000 | -41.3% | 47,617 | -46.4% | 0.01% | -40.0% |
Q2 2013 | $5,627,000 | – | 88,897 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |